Abstract
Objective
To investigate the different inhibition effects of different sequential usages of microtubule depolymerization drug and polymerization drug on tumor cells.
Methods
Three tumor cell lines including MCF-7, SK-OV3, A549 were incubated with paclitaxel (PTX) and/or vinorelbine (NVB) of different concentrations. The cyto-toxicity was examined by MTT test after incubating 72 h. According to different drugs and different sequences added to 96-well tissue culture plates, 5 groups were divided: PTX group (Group 1), NVB group (Group 2), PTX plus NVB group (Group 3), PTX first and NVB 4-h-later group (Group 4), and NVB first and PTX 4-h-later group (Group 5). Drug concentrations were 100% peak plasma concentration (PPC), 50% PPC, 25% PPC, 12.5% PPC, and 6. 25% PPC.
Results
The inhibition effects on the three tumor cell lines in Group 5 were stronger than those in the other four groups (P < 0.01). And the inhibition effects in Group 4 were not stronger than those in Groups 1, 2 or 3 (P > 0.1).
Conclusion
Using microtubule depolymerization drug first and then using microtubule polymerization drug has synergic inhibition effect on tumor cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Xu B. New theory of oncologic pharmacology. Beijing: People’s Medical Publishing House, 2005. 5.
Airoldi M, Cattel L, Pedani F. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer. Acta Oncol, 2003, 42: 186–194.
Martín M, Lluch A, Casado A, et al. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol, 2000, 11: 85–89.
Tao P, Li ZL, Li H. Clinical study of navelbine plus paclitaxel for patients with advanced breast cancer. Chin Oncol (Chinese), 2006, 16: 61–62.
Han WL, Chen CP. Vinorelbine plus paclitaxel for the treatment of 22 cases of metastatic post-operation breast cancer patients. J Chin Physic (Chinese), 2006, 8: 1281.
Gerasimos A. Docetaxel plus vinorelbine for previously treated ovarian cancer with platinum and paclitaxel. Proc Am Soc Oncol, 2002, 21: 895.
Guan CN, Cai LZ, Li SJ, et al. Effects of docetaxel plus vinorelbine for the treatment of advanced non small lung cancer. Chin J Hospital Pharm (Chinese), 2006, 26: 989–990.
Koletsky AJ, Guerra ML, Kronish L. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J, 2003, 9: 286–292.
Han R. Carcinoma chemotherapeutic prevention and pharmacotherapy. Beijing: Peking Medical University and Peking Union Medical College Press, 1991. 273–283.
Manfredi JJ, Horwitz SB. Taxol, an anti-mitotic agent with a new mechanism of action. Pharmac Ther, 1984, 25: 83.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Jia, Y., Lei, K., Yuan, Z. et al. Inhibition effects of using sequential microtubule depolymerization drug and polymerization drug on tumor cells. Chin. -Ger. J. Clin. Oncol. 7, 719–722 (2008). https://doi.org/10.1007/s10330-008-0132-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-008-0132-x